The Israeli startup Sealantis was sold for $ 25 million and royalties from future sales to AMS

wwwww

by Ifi Reporter Category:Hitech Jan 31, 2019

The Israeli company, Sealantis which was established on the basis of technology developed at the Technion, was sold for $ 25 million and royalties from future sales to Advanced Medical Solutions (AMS).

The company develops medical adhesives based on technology from the Technion, which mimics the mechanism of adhesion of algae to rocks under water. "This is a basic research inspired by a natural phenomenon that developed into applied technology, was patented and finally became a product that will enable hundreds of thousands of patients to be treated."
Advanced Medical Solutions (AMS), a leading provider of wound care products, sells products in 75 countries. This is her first acquisition in Israel, with Sintatis staying in Israel and becoming an innovation center for the international group. AMS owns seven branches throughout Europe and employs more than 600 employees.
Sealantis develops medical sealants based on algae-based adhesive to prevent leaks after surgical procedures. The company was established under the auspices of the Amit Institute of the Technion under the leadership of Prof. Havazelet Bianco-Peled of the Faculty of Chemical Engineering, a world-renowned researcher in bio-medical polymers.
The application of the technology enables the development of products for medical use. The company's focus today is on surgical seals designed to stop bleeding, prevent leakage of digestive tract contents into the abdominal cavity, prevent spleen leakage and a variety of other applications.
The main advantage of the technology is the fact that it is based on a polymer produced from algae, which does not contain proteins, and therefore the risk of infection or allergy is significantly lower than competing products produced from animals. The product does not require refrigerated transport and storage, it can be applied by application or spraying and is also suitable for use in laparoscopic surgery.
Tomer Fuchs, the company's CEO, says that the connection with AMS increases the chances of finding the company's products in each operating room: "The journey of Clementis is underway. The merger into AMS is an important milestone in the realization of our vision to enable medical teams worldwide to prevent serious surgical complications due to the products of Cilantis. Following the merger, AMS will enjoy our scientific and engineering capabilities as an Israeli start-up company in the field of biotechnology, which includes innovation and the ability to bring simple and original solutions to complex challenges. AMS plans to expand operations in Israel, which will allow it to expand into new and significant directions. "
The team consists of a small number of employees, with a majority of women including chemical engineers, biotech engineers, Technion graduates and other universities.
Prof. Havazelet Bianco-Peled: "After we cracked the fastening mechanism of acceleration we realized that it could be applied to wet surfaces in the human body and we patented it out of the realization that there might be commercial potential. The right to be involved in the development of a product intended to reach hospitals and to assist patients, and it is an interesting experience to commercialize a patent. "I was exposed to areas that I would not have known had I only stayed in the laboratory, an experience I would not have given up even though research is my main focus."
Today, Prof. Bianco-Peled continues to study the field of polymers for medical uses.
Prof. Wayne Kaplan, Vice President of Research at the Technion, said: "This is an inspiring case that shows how basic research has become my application and led to the establishment of a company." At the end of this long process, it is acquired by a leading international company and proves how university-level research can affect sex I am sure that Celentis will serve as an example for faculty and students at the Technion and in academia as a whole, about the potential impact of science on society. "

 

 

 

827 Views

Comments

No comments have been left here yet. Be the first who will do it.
Safety

captchaPlease input letters you see on the image.
Click on image to redraw.

ABOUT IFI TODAY

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum

Testimonials

No testimonials. Click here to add your testimonials.